Hyperglycemia in patients treated with the pan-PI3K inhibitor buparlisib (BKM120): characterization, management, and assessment for pharmacodynamics

被引：0
|
作者：
Azaro, A. [1 ]
Rodon, J. [1 ]
Vansteenkiste, J. F. [2 ]
Ando, Y. [3 ]
Doi, T. [4 ]
Mills, D. [5 ]
Sarr, C. [6 ]
Di Tomaso, E. [7 ]
Massacesi, C. [8 ]
Naumann, R. W. [9 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Univ Hosp Gasthuisberg, Resp Oncol Unit, B-3000 Louvain, Belgium
[3] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Nagoya, Aichi, Japan
[4] Natl Canc Ctr Hosp, Gastrointestinal Oncol Div, Chiba, Japan
[5] Novartis Pharma AG, Stat, Basel, Switzerland
[6] Novartis Pharma AG, Modeling, Basel, Switzerland
[7] Novartis Inst Biomed Res, Cambridge, MA USA
[8] Novartis Oncol, Global Clin Program, Paris, France
[9] Carolinas Med Ctr, Div Gynecol Oncol, Charlotte, NC 28203 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
884
引用
收藏
页码：S186 / S186
页数：1
相关论文
共 50 条
  • [31] Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC)
    Saura, C.
    Burris, H.
    Arteaga, C. L.
    Mayer, I.
    Germa, C.
    Fretault, N.
    Sternberg, D.
    Trandafir, L.
    Massacesi, C.
    Rodon, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S96 - S96
  • [32] Phase Ib study of oral pan-PI3K BKM120 in combination with the oral MEK1/2 inhibitor GSK120212 in patients with selected advanced solid tumors and RAS / BRAF mutations
    Janku, F.
    Stathis, A.
    Perez-Garcia, J.
    Wainberg, Z.
    Paz-Ares, L.
    Vansteenkiste, J.
    Van Cutsem, E.
    Le, N.
    Zubel, A.
    Bedard, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S162 - S162
  • [33] PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest
    Sadeghi, Soroush
    Esmaeili, Shadi
    Pourbagheri-Sigaroodi, Atieh
    Safaroghli-Azar, Ava
    Bashash, Davood
    TURKISH JOURNAL OF HEMATOLOGY, 2020, 37 (03) : 167 - 176
  • [34] The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma
    Martin, Sally
    Gan, Zhen Ying
    Fitter, Stephen
    To, Luen B.
    Zannettino, Andrew C. W.
    LEUKEMIA RESEARCH, 2015, 39 (03) : 380 - 387
  • [35] Correction to: Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
    Xin Peng
    Shaolu Zhang
    Wenhui Jiao
    Zhenxing Zhong
    Yuqi Yang
    Francois X. Claret
    Moshe Elkabets
    Feng Wang
    Ran Wang
    Yuxu Zhong
    Zhe-Sheng Chen
    Dexin Kong
    Journal of Experimental & Clinical Cancer Research, 40
  • [36] Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
    Bendell, Johanna C.
    Rodon, Jordi
    Burris, Howard A.
    de Jonge, Maja
    Verweij, Jaap
    Birle, Diana
    Demanse, David
    De Buck, Stefan S.
    Ru, Qinhua C.
    Peters, Malte
    Goldbrunner, Michael
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 282 - 290
  • [37] Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120
    Bashash, Davood
    Delshad, Mahda
    Safaroghli-Azar, Ava
    Safa, Majid
    Momeny, Majid
    Ghaffari, Seyed H.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2017, 91 : 1 - 8
  • [38] Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor
    Munakata, Wataru
    Tobinai, Kensei
    LANCET HAEMATOLOGY, 2018, 5 (04): : E134 - E135
  • [39] Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without P13K pathway activation: A phase II, randomized, double-blind, placebo-controlled study - BELLE-4
    Martin, M.
    Batista, N.
    Shtivelband, M.
    Chan, A.
    Delaloge, S.
    Dirix, L.
    Lee, S. C.
    Le Mouhaer, S.
    Nanni, S.
    DiTomaso, E.
    Urban, P.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2013, 73
  • [40] A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors
    Baselga, J.
    De Jonge, M. J.
    Rodon, J.
    Burris, H. A., III
    Birle, D. C.
    De Buck, S. S.
    Demanse, D.
    Ru, Q. C.
    Goldbrunner, M.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345